James B. McMahon - Concepedia

Author

James B. McMahon

Also Known As

J B McMahon, J MCMAHON, J McMahon, J. B. MCMAHON, J. B. McMAHON, J. B. McMahon, J. McMahon, J.B. McMahon, JAMES B. MCMAHON, JAMES B. McMAHON

243

Publications

11.6K

Citations

H-Index

147

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research Frederick National Laboratory for Cancer Research Target (United States)Science Applications International Corporation (United States)

About

James B. McMahon is an author at National Cancer Institute specializing in medicine, pharmacology, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	81	6.2K
2	Natural Sciences	21	27	1.8K
3	Engineering	10	10	577
4	Public Health	1	1	36
5	Behavioral Sciences	1	1	23

James B. McMahon

151

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development Michael R. Boyd, Kirk R. Gustafson, James B. McMahon, Antimicrobial Agents and Chemotherapy Viral ReplicationImmunologyEscherichia ColiAntiviral DrugSimian Immunodeficiency Virus	1997	607
HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum Yoel Kashman, Kirk R. Gustafson, Ray W. Fuller, Journal of Medicinal Chemistry	1992	546
Isolation and Characterization of Griffithsin, a Novel HIV-inactivating Protein, from the Red Alga Griffithsia sp. Toshiyuki Mori, Barry R. O’Keefe, Raymond C. Sowder, Journal of Biological Chemistry	2004	444
Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity David A. Cooney, Maha Dalal, Hiroaki Mitsuya, Biochemical Pharmacology MedicineHtlv-iii InfectivityAntiviral Drug DevelopmentAntiviral TherapyVirology	1986	322
Circulins A and B. Novel human immunodeficiency virus (HIV)-inhibitory macrocyclic peptides from the tropical tree Chassalia parvifolia. Kirk R. Gustafson, Raymond C. Sowder, Louis E. Henderson, Journal of the American Chemical Society GlycobiologyImmunologyAltmetric Attention ScorePeptide ScienceAntiviral Drug	1994	304
Broad-Spectrum<i>In Vitro</i>Activity and<i>In Vivo</i>Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family<i>Coronaviridae</i> Barry R. O’Keefe, Barbara Giomarelli, Dale L. Barnard, Journal of Virology	2009	301
The guttiferones, HIV-inhibitory benzophenones from Symphonia globulifera, Garcinia livingstonei, Garcinia ovalifolia and Clusia rosea Kirk R. Gustafson, John W. Blunt, Murray H. G. Munro, Tetrahedron Medicinal ChemistryMedicineHiv-inhibitory BenzophenonesHerbal MedicineClusia Rosea	1992	286
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component Barry R. O’Keefe, Fakhrieh Vojdani, Viviana Buffa, Proceedings of the National Academy of Sciences EngineeringAntiviral DrugDrug ResistanceScaleable ManufactureHuman Retrovirus	2009	259
Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation Thomas Fabre, Alex Barron, Stephen M. Christensen, Science Immunology	2023	243
Oligosaccharide and Glycoprotein Microarrays as Tools in HIV Glycobiology Eddie W. Adams, Daniel M. Ratner, Heidi R. Bokesch, Chemistry & Biology GlycobiologyImmunologyPolysaccharideHivMedicine	2004	233

Page 1